GENE ONLINE|News &
Opinion
Blog

2020-12-18| In-DepthSpecial

Coexistence of Thrombophilic Factors and Hemophilia – A Blessing in Disguise?

by GeneOnline
Share To
The most common treatment for hemophilia is a factor replacement therapy, but it comes with challenges like frequent infusions, cost, development of inhibitors, etc. To overcome these limitations, new approaches were explored, such as factors with an extended half-life, inhibition of anticoagulant proteins, and gene therapy.
In normal circumstances, the coexistence of two disorders would enhance distress in an already suffering individual, but what would happen if thrombophilia and hemophilia coexist in an individual? Will they complement each other?

GO Prime with only $1.49 now

LATEST
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
2024-04-12
Oncology’s New Drugs on the Horizon (I): Cancer Immunotherapy and Targeted Therapy
2024-04-12
Vertex Pharmaceuticals Makes $4.9 Billion Bet on Kidney Disease Treatment through Alpine Immune Acquisition
2024-04-11
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
2024-04-10
Pharmacogenomics (PGx) Shaping the Dynamic APAC Regions
2024-04-10
Connecting Biotech Ecosystems: Success of Los Angeles Event Sets Stage for APAC-US Collaboration
2024-04-10
Innovating Prostate Cancer Care: SYNC-T, Proteogenomics, and Culturally Tailored Education at AACR 2024
2024-04-10
EVENT
Scroll to Top